Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review [CARE DELIVERY]

Conclusion: Potential costs associated with drug wastage are considered in only one third of modern cost-effectiveness models. The impact of wastage on calculated ICERs and drug acquisition costs is potentially substantial. The modeling of wastage in base-case and sensitivity analyses is recommended for future economic evaluations of new intravenous therapies for hematologic malignancies.
Source: Journal of Oncology Practice - Category: Cancer & Oncology Authors: Tags: Pharmacoeconomics, Treatment related issues, Quality of care, Cost of care, Pharmacoeconomics, Financial resources, Leukemia, Lymphoma, Chemotherapy, Chemotherapy, Hematology CARE DELIVERY Source Type: research